NCT04867603 is a clinical trial of [Ga-68]PSMA in Prostate Cancer, sponsored by Norbert Avril, M.D..

Who is sponsoring NCT04867603?

NCT04867603 is sponsored by Norbert Avril, M.D..

What drugs are being tested in NCT04867603?

Interventions in NCT04867603: [Ga-68]PSMA, PET/CT imaging.

What condition does NCT04867603 study?

NCT04867603 studies Prostate Cancer.

Is NCT04867603 still recruiting?

NCT04867603 is currently completed. Last updated 19 December 2023.

Last reviewed 2023-12-19 · How we verify

NCT04867603

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Completed Last updated 19 December 2023

What this trial tests

trial testing [Ga-68]PSMA in Prostate Cancer in 16 participants. Completed in 3 October 2022.

Timeline

29 June 2021

Primary endpoint
3 October 2022

3 October 2022

Quick facts

Lead sponsor	Norbert Avril, M.D.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	16
Start date	29 June 2021
Primary completion	3 October 2022
Estimated completion	3 October 2022
Sites	1 location across United States

Drugs / interventions tested

[Ga-68]PSMA — full drug profile →
PET/CT imaging

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Norbert Avril, M.D. — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen (\[Ga-68\]PSMA) for characterization of prostate abnormalities.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Role of [<sup>68</sup>Ga]PSMA PET/CT for Clinical Suspicion of Prostate Cancer in Patients with or without Previous Negative Biopsy: A Systematic Review.
Caracciolo M, Castello A, Urso L, Borgia F, et al · · 2022 · cited 11× · PMID 36291820 · DOI 10.3390/cancers14205036

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04867603 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Norbert Avril, M.D.
Last refreshed: 19 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04867603.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing